Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Giornale Italiano di Dermatologia e Venereologia 2008 April;143(2) > Giornale Italiano di Dermatologia e Venereologia 2008 April;143(2):139-49

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA

A Journal on Dermatology and Sexually Transmitted Diseases


Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,014


eTOC

 

REVIEWS  VACCINES IN DERMATOLOGICAL EXPERIMENTAL THERAPY


Giornale Italiano di Dermatologia e Venereologia 2008 April;143(2):139-49

language: English

Immunotherapeutic strategies for the treatment of malignant melanoma

Alexeev V. 1,2, Mucci T. 1, Igoucheva O. 1

1 Department of Dermatology and Cutaneous Biology Jefferson Medical College Thomas Jefferson University, Philadelphia, PA, USA
2 Jefferson Vaccine Center Thomas Jefferson University, Philadelphia, PA, USA


PDF  


The incidence of cutaneous malignant melanoma is increasing at a faster rate than any other cancer worldwide. Despite new advances in surgical management of melanoma, this malignancy remains one of the most aggressive and intractable to treat among other solid tumors. Continuous search for better therapeutics led to the development of various immunological approaches applicable to the treatment of this melanocytic malignancy. Multiple peptide, dendritic cell, adjuvant, lymphocyte, and virus-based strategies were established and tested in preclinical and clinical studies with varying degrees of clinical success. However, the most recent investigations in melanoma immunotherapy have clearly demonstrated that complex vaccines and the combination of different approaches, such as the use of dendritic cell vaccines in conjunction with costimulatory molecules, are superior to conventional immunization protocols in induction of tumor-specific immune responses. These recent studies open new perspectives for the development of efficient melanoma immunotherapeutics suitable for the treatment of primary and metastatic disease.

top of page

Publication History

Cite this article as

Corresponding author e-mail